Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by M101on Feb 04, 2022 4:08pm
111 Views
Post# 34399403

RE:losing patience

RE:losing patienceI agree with the sentiment, but it is based on the 2015-16 comments not promises of the consultants who stood to gain most by an early exit.

We now know that no big pharma player was ever going to bet early on the misfolded-protein-only epitope hypothesis, not because there's anything wrong with it but because they simply don't take those kinds of risks except as developed in-house, and even in-house it's only because of internal politics.  This is why Goldstein was telling early shareholders that everyone in the biz advised them to take it private.  

So we're 6-years in facing a trials system designed between oligopolists and their captured regulators, and their banker-analyst echo chamber, to exclude small player competition.  What Gene and Elliot attempted was probably mostly about ego and greed, but it was also audacious
and remains so.  

This is why with a couple of big pharma competitors' AD programs on the ropes we need Gene to either step up or step aside.  He needs to recognize that no one wants to see an AD clinical success right now more than the FDA. The window is open now to jump ship and start crediting the regulators for their recent turn-around, ignoring whatever insider politics may be behind it.
He has to know full well that at his level respect does not come from loyalty.

The share price may well remain "lacklustre" all year, it means nothing to those with patience because in the big picture things are looking pretty good. 
  













<< Previous
Bullboard Posts
Next >>